Real Time Touch

new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)

Real Time Touch

Nogra Pharma Limited patents

Recent patent applications related to Nogra Pharma Limited. Nogra Pharma Limited is listed as an Agent/Assignee. Note: Nogra Pharma Limited may have other listings under different names/spellings. We're not affiliated with Nogra Pharma Limited, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "N" | Nogra Pharma Limited-related inventors

Compounds and their salts specific to the ppar receptors and the egf receptors and their use in the medical field

The present invention relates to compounds comprising the general formula (I), in which R1 and R2, which may be identical or different, are selected from the group comprising —H or a linear or branched alkyl group having from 1 to 6 carbon atoms or together form an aromatic or aliphatic... Nogra Pharma Limited

Antisense oligonucleotides (odn) against smad7 and uses thereof in medical field

The invention relates to antisense oligonucleotidic sequences (ODN) against Smad7 suitably modified, and their uses in medical field as therapeutic biological agents, in particular in the treatment of chronic inflammatory bowel disease, such as Crohn's disease and ulcerative colitis.... Nogra Pharma Limited

Methods and compositions for treating a subject with a smad7 antisense oligonucleotide

The present invention relates to treatment of inflammatory bowel disease (e.g., Crohn's disease and ulcerative colitis) using antisense nucleotides that are directed against polymorphic forms (e.g., those containing single nucleotide polymorphisms) of the SMAD7 mRNA. The invention thus relates to treatment methods for subjects having polymorphic forms of SMAD7 and... Nogra Pharma Limited

Methods for dosing and monitoring smad7 antisense oligonucleotide treatment using biomarker levels

Methods of treating IBD in a subject using an anti-SMAD7 therapy, such as a SMAD7 antisense oligonucleotide, to reduce CCL20, IL8, or TNFα levels are disclosed. Methods of treating and managing IBD in a subject using an anti-SMAD7 therapy, such as a SMAD7 antisense oligonucleotide, based on CCL20, IL8, or... Nogra Pharma Limited

Bicyclic heterocycles capable of modulating t-cell responses, and methods of using same

The present disclosure is directed in part to bicyclic heterocycles, such as a compound represented by formula (I) or (II) as disclosed herein, and their use in treating medical disorders, such as immune inflammatory disorders such as Crohn's disease, ulcerative colitis, rheumatic disorders, psoriasis, and allergies. The compounds are contemplated... Nogra Pharma Limited

Alkylamido compounds and uses thereof

Disclosed herein are compounds that may be specific to PPAR and/or EGF receptors, and methods of making and using same.... Nogra Pharma Limited

Aryl receptor modulators and methods of making and using the same

The present invention is generally directed towards compounds capable of binding the aryl hydrocarbon receptor and modulating its activity, methods of treating inflammatory conditions such as Crohn's disease using such compounds, and pharmaceutical compositions comprising such compounds. Also provided are methods of increasing levels of IL-22 in a subject and/or... Nogra Pharma Limited

Antisense compositions and methods of making and using same

The present invention provides pharmaceutical formulations for oral administration of antisense oligonucleotides, such as antisense oligonucleotides against SMAD7. The pharmaceutical formulations can be used to treat Crohn's disease, ulcerative colitis and chronic inflammatory bowel disease.... Nogra Pharma Limited

Methods for preventing or reducing colon carcinogenesis

The present invention is directed in part to methods of preventing or reducing colon carcinogenesis comprising administering to a patient at risk of colorectal cancer, a pharmaceutical preparation comprising disclosed chemopreventive. In another aspect, the invention is directed to methods attenuation of oxygen free radicals comprising administrating to a patient... Nogra Pharma Limited

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009


This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. is not affiliated or associated with Nogra Pharma Limited in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Nogra Pharma Limited with additional patents listed. Browse our Agent directory for other possible listings. Page by